Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:FLGTNASDAQ:FTRENASDAQ:RDNTNASDAQ:VCYT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeFLGTFulgent Genetics$20.61+0.3%$18.69$14.57▼$25.11$627.45M1279,924 shs298,531 shsFTREFortrea$4.18$5.72$3.97▼$28.41$378.29M2.151.80 million shs1.69 million shsRDNTRadNet$55.19-0.2%$53.26$45.00▼$93.65$4.14B1.46686,825 shs418,124 shsVCYTVeracyte$26.96+0.9%$30.21$19.73▼$47.32$2.11B2.14896,573 shs878,858 shs7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceFLGTFulgent Genetics+0.29%+0.44%+13.68%+33.40%-1.15%FTREFortrea0.00%-1.42%-33.97%-69.82%-83.08%RDNTRadNet-0.18%-2.78%+5.99%-0.50%-6.99%VCYTVeracyte+0.90%-1.61%-14.09%-22.44%+29.68%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationFLGTFulgent Genetics3.7362 of 5 stars2.32.00.04.12.74.20.6FTREFortrea3.0398 of 5 stars3.91.00.00.02.00.82.5RDNTRadNet4.3352 of 5 stars3.73.00.04.63.52.50.0VCYTVeracyte4.2865 of 5 stars4.43.00.04.32.70.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceFLGTFulgent Genetics 2.50Moderate Buy$24.0016.45% UpsideFTREFortrea 1.86Reduce$15.00258.85% UpsideRDNTRadNet 3.40Buy$69.7526.38% UpsideVCYTVeracyte 2.70Moderate Buy$40.9051.71% UpsideCurrent Analyst Ratings BreakdownLatest VCYT, RDNT, FTRE, and FLGT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/22/2025FTREFortreaCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral5/14/2025FTREFortreaCowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingHold ➝ Hold5/14/2025FTREFortreaMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$10.00 ➝ $8.005/14/2025FTREFortreaThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$7.00 ➝ $5.005/13/2025FTREFortreaBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetUnderweight ➝ Underweight$6.00 ➝ $5.005/8/2025VCYTVeracyteUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$49.00 ➝ $42.005/8/2025VCYTVeracyteNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$51.00 ➝ $41.005/6/2025FLGTFulgent GeneticsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$16.00 ➝ $23.005/5/2025FLGTFulgent GeneticsRaymond JamesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$24.00 ➝ $25.005/2/2025FTREFortreaTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageHold$7.004/11/2025RDNTRadNetTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$88.00 ➝ $74.00(Data available from 5/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookFLGTFulgent Genetics$292.45M2.15$4.03 per share5.12$38.24 per share0.54FTREFortrea$2.69B0.14$0.67 per share6.28$19.58 per share0.21RDNTRadNet$1.87B2.22$2.93 per share18.81$11.79 per share4.68VCYTVeracyte$463.39M4.56$0.06 per share442.29$14.30 per share1.89Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateFLGTFulgent Genetics-$167.82M-$1.33N/AN/AN/A-59.39%-1.81%-1.66%8/1/2025 (Estimated)FTREFortrea-$3.40M-$8.79N/A3.271.78-10.99%2.00%0.80%8/11/2025 (Estimated)RDNTRadNet$3.04M-$0.43N/A104.13N/A-0.25%4.29%1.45%8/5/2025 (Estimated)VCYTVeracyte-$74.40M$0.41N/A37.44N/A-2.18%3.02%2.80%8/5/2025 (Estimated)Latest VCYT, RDNT, FTRE, and FLGT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2025Q1 2025FTREFortrea-$0.07$0.02+$0.09-$6.25$609.63 million$651.30 million5/2/2025Q1 2025FLGTFulgent Genetics-$0.18$0.04+$0.22-$0.37$71.26 million$73.46 million3/3/2025Q4 2024FTREFortrea$0.36$0.18-$0.18-$0.68$703.22 million$697.00 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthFLGTFulgent GeneticsN/AN/AN/AN/AN/AFTREFortreaN/AN/AN/AN/AN/ARDNTRadNetN/AN/AN/AN/AN/AVCYTVeracyteN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioFLGTFulgent GeneticsN/A4.414.41FTREFortrea0.741.181.18RDNTRadNet0.892.162.16VCYTVeracyteN/A5.084.79Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipFLGTFulgent Genetics48.06%FTREFortreaN/ARDNTRadNet77.90%VCYTVeracyteN/AInsider OwnershipCompanyInsider OwnershipFLGTFulgent Genetics33.11%FTREFortrea0.12%RDNTRadNet5.12%VCYTVeracyte1.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableFLGTFulgent Genetics1,01030.44 million20.87 millionOptionableFTREFortrea18,00090.50 million89.59 millionOptionableRDNTRadNet8,97075.03 million70.24 millionOptionableVCYTVeracyte79078.32 million76.49 millionOptionableVCYT, RDNT, FTRE, and FLGT HeadlinesRecent News About These CompaniesVeracyte, Inc. (NASDAQ:VCYT) Given Average Rating of "Moderate Buy" by BrokeragesMay 30 at 2:45 AM | marketbeat.comVoloridge Investment Management LLC Reduces Stock Holdings in Veracyte, Inc. (NASDAQ:VCYT)May 29 at 4:29 AM | marketbeat.comVeracyte, Inc. (VCYT) Presents Breakthrough Genomic Data to Predict Cancer Therapy Response at ASCOMay 29 at 12:57 AM | insidermonkey.comVeracyte Announces Multiple Abstracts To Be Presented at ASCO, Demonstrating Power of Decipher GRID to Advance New Prostate and Bladder Cancer ResearchMay 28 at 4:18 PM | businesswire.comVeracyte: Upgrading To NeutralMay 26, 2025 | seekingalpha.comPalisades Investment Partners LLC Acquires New Position in Veracyte, Inc. (NASDAQ:VCYT)May 24, 2025 | marketbeat.comMan Group plc Sells 294,029 Shares of Veracyte, Inc. (NASDAQ:VCYT)May 23, 2025 | marketbeat.comDeutsche Bank AG Has $3.22 Million Holdings in Veracyte, Inc. (NASDAQ:VCYT)May 23, 2025 | marketbeat.comVeracyte, Inc. (NASDAQ:VCYT) Shares Acquired by Nuveen Asset Management LLCMay 22, 2025 | marketbeat.comComparing Veracyte (NASDAQ:VCYT) and Grail (NASDAQ:GRAL)May 22, 2025 | americanbankingnews.comVeracyte, Inc. (NASDAQ:VCYT) Shares Sold by Virtus Investment Advisers Inc.May 21, 2025 | marketbeat.comD. E. Shaw & Co. Inc. Lowers Stock Holdings in Veracyte, Inc. (NASDAQ:VCYT)May 21, 2025 | marketbeat.comVeracyte to Participate in Upcoming Investor ConferencesMay 20, 2025 | businesswire.comPoint72 Asset Management L.P. Buys Shares of 523,162 Veracyte, Inc. (NASDAQ:VCYT)May 20, 2025 | marketbeat.comMIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Has $7.61 Million Position in Veracyte, Inc. (NASDAQ:VCYT)May 20, 2025 | marketbeat.comVeracyte, Inc. (NASDAQ:VCYT) Shares Sold by Bank of America Corp DEMay 20, 2025 | marketbeat.comBNP Paribas Financial Markets Sells 55,684 Shares of Veracyte, Inc. (NASDAQ:VCYT)May 20, 2025 | marketbeat.comVeracyte Stock Surges 30.9% in a Year: What's Driving the Rally?May 19, 2025 | zacks.comLazard Asset Management LLC Boosts Holdings in Veracyte, Inc. (NASDAQ:VCYT)May 19, 2025 | marketbeat.comResearch Analysts Set Expectations for Veracyte Q2 EarningsMay 18, 2025 | marketbeat.comParkman Healthcare Partners LLC Reduces Stock Holdings in Veracyte, Inc. (NASDAQ:VCYT)May 16, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeVCYT, RDNT, FTRE, and FLGT Company DescriptionsFulgent Genetics NASDAQ:FLGT$20.61 +0.06 (+0.29%) Closing price 05/29/2025 04:00 PM EasternExtended Trading$20.59 -0.02 (-0.09%) As of 05/29/2025 05:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Fulgent Genetics, Inc., together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases. Its therapeutic development solutions focus on developing drug candidates for treating a range of cancers using a nanoencapsulation and targeted therapy platform to enhance the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. The company operates picture genetics platform, which includes gene probes, data suppression and comparison algorithms, adaptive learning software, and proprietary laboratory information management systems that helps customers to identify health markers in their personal DNA. It serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, municipalities and large corporations, and patients. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in El Monte, California.Fortrea NASDAQ:FTRE$4.18 0.00 (0.00%) Closing price 05/29/2025 04:00 PM EasternExtended Trading$4.18 0.00 (-0.12%) As of 05/29/2025 05:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Fortrea Holdings Inc., a contract research organization, primarily engages in the provision of biopharmaceutical product and medical device development services worldwide. The company operates through two segments: Clinical Services and Enabling Services. The Clinical Services segment provides across the clinical pharmacology and clinical development spectrum. The Enabling Services segment provides patient access and clinical trial technology solutions to customers that streamline complex randomization and optimize the trial drug supply process. The company offers delivery models that include full service, functional service provider, and hybrid service structures. It also offers phase I-IV clinical trial management, differentiated technology enabled trial solutions, and post approval services, as well as consulting services. The company serves pharmaceutical, biotechnology, and medical device organizations. Fortrea Holdings Inc. was incorporated in 2023 and is headquartered in Durham, North Carolina.RadNet NASDAQ:RDNT$55.19 -0.10 (-0.18%) Closing price 05/29/2025 04:00 PM EasternExtended Trading$55.17 -0.02 (-0.04%) As of 05/29/2025 07:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.RadNet, Inc., together with its subsidiaries, provides outpatient diagnostic imaging services in the United States. The company operates in two segments: Imaging Centers and Artificial Intelligence. Its services include magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other related procedures, as well as multi-modality imaging services. The company also develops and sells computerized systems that distribute, display, store, and retrieve digital images; offers picture archiving communications systems and related services; and develops and deploys AI suites to enhance radiologist interpretation of breast, lung, and prostate images, as well as AI solutions for prostate cancer screening. RadNet, Inc. was founded in 1981 and is headquartered in Los Angeles, California.Veracyte NASDAQ:VCYT$26.96 +0.24 (+0.90%) Closing price 05/29/2025 04:00 PM EasternExtended Trading$26.96 -0.01 (-0.02%) As of 05/29/2025 04:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Veracyte, Inc. engages in the research, development and commercialization of diagnostic products. The firm's portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H. Anderson and Y. Douglas Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Hormel Stock Near Lows, But Tariff Relief Could Boost Outlook Salesforce’s Stock Price Presents an Opportunity to Buy NVIDIA Will Set a New High Soon, Then Keep Rallying, Here’s Why Goodyear Stock Surges 28% in 2025: Is More Growth Ahead? Intel's Loss Is Broadcom's Gain as AVGO Dominates Networking Target's Big Bet: Is It a Cheap Stock or a Value Trap? Dividend Investors Looking for an Edge? 3 Stocks Insiders Bought Toyota Supercharges Joby: $250M Capital Infusion Ignites Stock Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
